Cancer risk among patients with multiple sclerosis and their parents.
Silvia
S
Hofer
Michael
M
Linnebank
Michael
M
Weller
S
S
Bahmanyar
S M
SM
Montgomery
J
J
Hillert
A
A
Ekbom
T
T
Olsson
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D001932:Brain Neoplasms / Q000139:chemically induced / Q000453:epidemiology* / Q000503:physiopathology; D005190:Family; D005910:Glioma / Q000139:chemically induced / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology; D000069442:Natalizumab; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology; D010290:Parents; D012306:Risk
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab